HilleVax, Inc. (NasdaqGM: HLVX)
Health Care · Biotechnology · US
$—
— today · — 1Y
HilleVax, Inc. (NasdaqGM: HLVX) operates in the Biotechnology industry within the Health Care sector.
trading between 2.05 and 2.13.
Tweenvest scores HilleVax, Inc. across four factors: quality 27/100. Its strongest factor is quality.
HLVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.43
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $2.13
- 52-week low
- $2.05
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 14
- Next earnings
- —
About HilleVax, Inc.
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.
- Founded
- 2019
- Listed since
- Apr 29, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.66 | +0.64% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.00 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €875.60 | -2.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $144.51 | -0.39% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.